Introduction: Type 2 diabetes (T2D) is the leading
. Methods: Efficacy and safety data were pooled from nine 24-week, randomized, placebo-controlled clinical trials.
Results: The majority (56-61%) of patients were women aged \65 years with glycated hemoglobin (A1C) 8.1-8.2%; half of the patients had a T2D duration C5 years. Mean change from baseline in A1C was significantly greater with saxagliptin 2.5 (-0.6%, P = 0.036 vs placebo) and 5 mg/day (-0.9%, P\0.001 vs placebo) compared with placebo (-0.2%).
There were numerically greater reductions in fasting plasma glucose and 2-h postprandial glucose, and a significantly greater proportion of patients achieved A1C \7% with saxagliptin 5 mg/day (44.8%) compared with placebo (20.0%, P = 0.004 vs placebo). The incidence of hypoglycemia was not significantly different across groups (16.2% in the saxagliptin 5-mg/day, 12.2% in the saxagliptin 2.5-mg/day, and 11.3% in the placebo groups).
Conclusion:
These results suggest that saxagliptin 2.5 and 5 mg/day improve glycemic control and are generally well tolerated in patients with T2D and moderate CKD.
INTRODUCTION
Worldwide, diabetes is the leading cause of chronic kidney disease (CKD) [1] , which is defined by an estimated glomerular filtration rate (eGFR) of \60 mL/min/1.73 m 2 or an albumin/creatinine ratio C30 mg/g for more than 3 months [2] . In the United States, the prevalence of CKD among individuals with diabetes is estimated to be *40% based on eGFR and/or albuminuria [3] . (Fig. 1a ). There were numerically greater, but not statistically significant, reductions from baseline in FPG ( Fig. 1b; Overall, AEs were reported more frequently with saxagliptin treatment compared with placebo (Table 2 ). AEs and SAEs related to kidney function were infrequent. The proportion of patients with increased blood creatinine was generally similar with placebo (5.6%) and saxagliptin treatment (4.4-8.2%).
There was 1 SAE of acute renal failure in the saxagliptin 2.5-mg/day group and none in the saxagliptin 5-mg/day and placebo groups. The 61-year-old woman was overweight and had a history of hypertension, hypercholesterolemia, hypertriglyceridemia, and probable baseline CKD exacerbated by relative volume depletion and concomitant medications. Saxagliptin was discontinued, and the event resolved following treatment. The acute renal failure was considered unlikely to be related to saxagliptin. In general, AEs were similar with saxagliptin 2.5 and 5 mg/day, although AEs related to pain were more frequent with saxagliptin 5 than 2.5 mg/day. The proportion of patients with hypoglycemia was numerically greater, but not significantly different, compared with placebo (11.3%) in the saxagliptin 2.5-mg/day (12.2%, P = 1.000) and 5-mg/day groups (16.2%, P = 0.464). At 24 weeks, there were small mean increases in eGFR from baseline in all treatment groups (Fig. 3) .
DISCUSSION
Impaired renal function is common in patients with T2D, especially in those C65 years [4], and is independently associated with increased mortality, cardiovascular events, and hospitalization [18, 19] . Our results using data pooled from 9 randomized clinical trials of saxagliptin 2.5 and 5 mg/day are in agreement with the results of a previously reported 12-week Fig. 2 Proportion of patients achieving A1C\7% at week 24. A1C glycated hemoglobin, NS nonsignificant, SAXA saxagliptin clinical trial [21] with an extension to 52 weeks [22] of saxagliptin 2.5 mg/day (plus background antidiabetes medications) in patients with T2D
and moderate (CrCl 30 to \50 mL/min), severe (CrCl\30 mL/min and not receiving hemodialysis), or end-stage (receiving hemodialysis) kidney disease. In that study, saxagliptin was well tolerated across all stages of CKD and reduced A1C, compared with placebo, in patients with moderate and severe CKD.
Limitations of this study include its post hoc nature, relatively small number of patients, and duration of 24 weeks. However, the results of 
